Bajaj Healthcare · risk themes across the available quarters.
Bear-case history
Export contributed only ₹50.1 crore (~30% of revenue) vs historical levels. Management expects 'revenue mix to gradually normalize towards historical levels as export improves and geopolitical conditions ease'. If geopolitical tensions persist, the 10-15% growth guidance could be at risk.
Three loss-making Tarapur plants were planned for divestment. Only one has been sold; two remain unsold. Management stated 'we are still on a lookout from a buyer' for the remaining units. Proceeds expected around ₹50 crore but timing remains uncertain, prolonging drag from loss-making operations.
While the 250kg peptide facility targets Q4 FY27 commissioning, commercial revenue won't start until 2028 due to customer qualification and validation requirements. Management explicitly stated 'without plant commercialization nothing happens' and confirmed 'commercial revenues could start coming in in the second half of 28'. Near-term growth depends entirely on existing businesses.
The MOU with ICT for fermentation-based vitamin C manufacturing 'will be a patented technology' but management acknowledged 'this is a long long way to go' with completion expected in 2029. This 8-9% revenue product faces continued import dependency for ~3+ years.